Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

A method for constructing an animal model of chronic liver cirrhosis with biliary atresia

A biliary atresia, animal model technology, applied in the direction of anti-animal/human immunoglobulin, animal husbandry, etc., can solve the problems of low repetition rate, insufficiency, waste, etc., and achieve long life cycle, high repetition rate, and lock rate. high effect

Active Publication Date: 2018-05-11
GUANGZHOU WOMEN AND CHILDRENS MEDICAL CENTER
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still many defects in the development of this model: 1. In the classic animal model of biliary atresia induced by injection of RRV within 24 hours after birth, although the acute inflammatory stage of biliary atresia can be simulated, newborn mice can show systemic jaundice, Coarse hair, low body weight, dark yellow urine, white clay-like stool, poor mental state, etc. However, the mice in this model could not survive to 14 days due to the strong immune response of the biliary system of newborn mice to RRV , the survival rate is extremely low; 2. In the animal model of biliary atresia induced by injection of high doses of RRV on the 4th or 5th day after birth, although the mice can survive to 15-20 days, the model is unstable and the repetition rate Low; the dose of injected virus stock solution is large, resulting in waste; most of the mice in this model showed symptoms of transient hepatitis, which did not conform to the clinical characteristics of patients with biliary atresia; according to anatomical observation, biliary atresia rarely occurred in this model; The model still cannot fully simulate the stage of biliary atresia in end-stage cirrhosis; therefore, the existing rotavirus-induced biliary atresia animal model can only simulate the acute inflammatory stage of clinical biliary atresia patients, and there is no sufficient evidence that the existing model Can simulate the stage of chronic cirrhosis or end-stage cirrhosis with biliary atresia
However, the existing animal models of biliary atresia cannot simulate the occurrence, development, and prognosis of the entire disease process of biliary atresia.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method for constructing an animal model of chronic liver cirrhosis with biliary atresia
  • A method for constructing an animal model of chronic liver cirrhosis with biliary atresia
  • A method for constructing an animal model of chronic liver cirrhosis with biliary atresia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] The experimental group was injection of anti-MDSCs drugs and RRV group (RRV+ anti Gr-1 group), the positive control group was only injection of RRV group (RRV group), and the negative control group was no injection of MDSCs drugs and RRV group (normal group). The construction method of sclerosing animal model, comprises the following steps:

[0030] (1) Balb / c neonatal mice were intraperitoneally injected with an anti-MDSCs drug [Anti-Mouse Ly-6G (Gr-1), referred to as Gr-1 antibody] within 24 hours of birth, and the first dose was 5ng per mouse ( Neonatal mice weigh approximately 1.6 g).

[0031] (2) Four hours after the injection of anti-MDSCs drugs, intraperitoneal injection of rhesus monkey rotavirus (MMU18006 virus strain, the titer of the virus suspension was 1×10 6 PFU), the injection dose was 20 μL per mouse, and the injection time of rhesus monkey rotavirus was also within 24 hours of the birth of Balb / c newborn mice.

[0032] (3) Multiple injections of anti-...

Embodiment 2

[0037] The experimental group was injection of anti-MDSCs drugs and RRV group (RRV+ anti Gr-1 group), the positive control group was only injection of RRV group (RRV group), and the negative control group was no injection of MDSCs drugs and RRV group (normal group). The construction method of sclerosing animal model, comprises the following steps:

[0038] (1) Balb / c neonatal mice were intraperitoneally injected with an anti-MDSCs drug [Anti-Mouse Ly-6G (Gr-1), referred to as Gr-1 antibody] within 24 hours of birth, and the first dose was 20ng per mouse ( Neonatal mice weigh approximately 1.6 g).

[0039] (2) Four hours after the injection of anti-MDSCs drugs, intraperitoneal injection of rhesus monkey rotavirus (MMU18006 virus strain, the titer of the virus suspension was 1×10 6 PFU), the injection dose was 20 μL per mouse, and the injection time of rhesus monkey rotavirus was also within 24 hours of the birth of Balb / c newborn mice.

[0040] (3) Multiple injections of anti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a construction method of an animal model for biliary atresia of chronic liver disease firstly utilizing a Gr-1 antibody to construct the construction method of the animal model for biliary atresia of chronic liver disease. The method comprises following steps: injecting rhesus monkey rotavirus within the 24 hours of neonatal mouse to induce a classic animal model for biliary atresia, firstly injecting the Gr-1 antibodies before rhesus monkey rotavirus is injected; injecting the Gr-1 antibodies multiple times after mouse are born on the 14th day to maintain the effective concentration range of the Gr-1 antibodies in the mouse; and injecting 5-20ng / 1.6g of Gr-1 antibodies to the mouse each time. The construction method of an animal model for biliary atresia of chronic liver disease has following beneficial effects: the model is capable of simulating the process of biliary atresia, development and prognosis, especially in the end-stage hepatocirrhosis phase.

Description

technical field [0001] The present invention relates to the technical field of animal model construction, and more specifically, relates to a method for constructing an animal model of chronic liver cirrhosis and biliary atresia. Background technique [0002] Biliary atresia (BA) is a progressive inflammatory cholangiopathy that occurs in infants and young children. It is a common disease that causes obstructive jaundice in infants and young children, and eventually leads to obstruction of extrahepatic and intrahepatic bile ducts and liver cirrhosis. The prognosis is poor and death occurs. High rate. In view of the ambiguity and complexity of the etiology of biliary atresia, the clinical research on biliary atresia is limited. People often construct animal models to simulate the symptoms of biliary atresia, so as to study its pathogenesis and try to find a way to treat the disease. [0003] Rhesus monkey rotavirus (rhesus rotavirus group A, RRV) is considered to have a cert...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/18
CPCA01K67/02
Inventor 张锐忠林泽锋陈严夏慧敏
Owner GUANGZHOU WOMEN AND CHILDRENS MEDICAL CENTER
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products